Upjohn

Formally, Pfizer will give Upjohn independence as part of a tax-optimizing strategy.

Merging with Upjohn, however, should also provide Mylan more flexibility to grow its difficult-to-manufacture chemically-complex biosimilar drug business and to pay down debt taken on for its Meda AB acquisition in 2016, while increasing diversification geographically and in branded drugs.

The Upjohn spin-off and all-stock merger unites blockbuster medications Viagra and Lipitor with Mylan's EpiPen.

Upjohn brings trusted, iconic brands, such as Lipitor (atorvastatin calcium), Celebrex (celecoxib) and Viagra (sildenafil), and proven commercialisation capabilities, including leadership positions in China and other emerging markets.

United States-based Pfizer has agreed to integrate its off-patent branded and generic established medicines business Upjohn with Mylan to set up a new global pharmaceutical company, it was reported yesterday.

Shares of Mylan NV (NASDAQ: MYL), which merged with Upjohn, were moving in the other direction.

Upjohn, the name of one of the companies Pfizer gobbled up during a spate of acquisitions in the 1990s and 2000s, sells off-patent and generic drugs that include the stars that drove Pfizer's growth: pain killers Celebrex and Lyrica, Norvasc for high blood pressure, Effexor for severe heartburn, Xanax for anxiety and Zoloft for depression.

The new company, to be based in the US and incorporated in Delaware, will be led by Michael Goettler, president of Pfizer's Upjohn unit, which sells older drugs that have lost patent protection.

The new company, to be based in the United States and incorporated in Delaware, will be led by Michael Goettler, president of Pfizer's Upjohn unit, which sells Pfizer's older drugs that have lost patent protection.

(NYSE: PFE) have inked a definitive agreement to combine Mylan with Upjohn, Pfizer's off-patent branded and generic established medicines business, creating a new global pharmaceutical company, the companies said on Monday.

Why can't they just pay teachers more to make them want to work more?" Alison Grubb, 31, Student (just graduated), Aberdeen "It's both good and bad because teachers may not have jobs but it's good because there is a shortage, their children won't miss out." Liana Upjohn, 19, student Perth, Australia "It takes away the face-toface interaction, you need while teaching.

Upjohn revenues were $3.1 billion, down 1%, with growth in China, primarily from Lipitor, Norvasc and Celebrex, partially offset by 3% operational decline in developed markets excluding Japan, primarily driven by lower revenues for: Viagra (-22% to $145 million) and Upjohn's authorized generic for Viagra in the U.S.

In Upjohn, the core issue was whether legal memoranda documenting interviews of employees conducted during an internal investigation were protected by the attorney-client privilege when the Internal Revenue Service demanded their disclosure in its own, subsequent investigation.

Other cases have expanded the underlying rationale of Upjohn to include former corporate employees and employees of domestic and foreign subsidiaries (see In re Coordinated Pretrial Proceedings in Petroleum Products Antitrust Litigation, 658 F.

He began his near 50-year career in the medical device industry with Upjohn as a research chemist in 1970.